The Effect of Gonadotropin-Releasing Hormone Agonist on Type I Collagen C-Telopeptide and N-Telopeptide: the Predictive Value of Biochemical Markers of Bone Turnover
article
OA: bronze
CC0
⤵ 3 in-corpus citations
Abstract
To evaluate the clinical utility of recently developed biochemical markers in the assessment of bone metabolism during GnRH agonist (GnRHa) treatment, we compared five bone resorption markers [C-telopeptide (CTX) and N-telopeptide (NTX) of type I collagen, hydroxyproline (Hpr), pyridinoline (Pyr), and deoxypyridinoline (Dpyr)] and two bone formation markers [total alkaline phosphatase (Alp) and osteocalcin (OC)]. Sixty-eight normally menstruating women were injected with a long-acting GnRHa once a month for 24 weeks for the treatment of endometriosis or leiomyoma. The mean percentage bone loss at the lumbar spine was 3.79% at the end of treatment. Although levels of all markers increased significantly as the treatment progressed, CTX and NTX exhibited the highest correlation coefficients between bone loss at 24 weeks and the seven markers measured at 0, 4, 12, 16, and 24 weeks of treatment. Serum estradiol levels were similarly suppressed during the treatment in both fast losers (whose bone loss was more than the mean) and slow losers (whose bone loss was less than the mean). However, significantly higher z-scores of bone resorption markers, but not of bone formation markers, were observed in the fast losers at 24 weeks of treatment, suggesting a more accelerated bone resorption in this group. Whereas the three highest z-scores at 24 weeks of treatment were CTX, NTX, and Dpyr (in that order), the highest z-score (P < 0.05) was observed for CTX in the fast losers. The subjects in the highest quartile of CTX, the highest, and second highest quartiles of NTX at 24 weeks of treatment experienced 2.1, 2.2, and 1.7 times more bone loss (P < 0.001), respectively, than those in the lowest quartiles. Furthermore, the subjects in the highest quartile of both CTX and NTX experienced 3.6 times more bone loss (P < 0.001) than those in the lowest quartile of both markers. These results indicate that both CTX and NTX are useful and sensitive markers for bone resorption in a hypoestrogenic state induced by GnRHa.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (50)
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone via openalex
- Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis via openalex
- Excretion of urinary n-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss via openalex
- Is It Possible to Prevent Bone Loss in Young Women Treated with Luteinizing Hormone-Releasing Hormone Agonists? via openalex
- “MEDICAL OOPHORECTOMY” USING A LONG-ACTING GNRH AGONIST-A POSSIBLE NEW APPROACH TO THE TREATMENT OF ENDOMETRIOSIS. via openalex
- Reduction of bone mineral density by gonadotropin‐releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration via openalex
- The Use of GnRH Agonists in the Medical Therapy of Endometriosis in the Woman with Pain via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. via openalex
- Urinary N-Telopeptides to Monitor Bone Resorption While on GnRH Agonist Therapy via openalex
- W1994863503 via openalex
- W1994965598 via openalex
- W1997291137 via openalex
- W2007614714 via openalex
- W2013079995 via openalex
- W2014736171 via openalex
- W2019056603 via openalex
- W2023471859 via openalex
- W2027858461 via openalex
- W2030341676 via openalex
- W2031495520 via openalex
- W2034196869 via openalex
- W2038120841 via openalex
- W2050399407 via openalex
- W2063103074 via openalex
- W2064536785 via openalex
- W2074704125 via openalex
- W2085652742 via openalex
- W2093580401 via openalex
- W2101280309 via openalex
- W2122107555 via openalex
- W2129449855 via openalex
- W2131993528 via openalex
- W2153895111 via openalex
- W2287757320 via openalex
- W2467395168 via openalex
- W4285719527 via openalex
- W6607058909 via openalex
- W6646848868 via openalex
- W6652551478 via openalex
- W6657492320 via openalex
- W6675357198 via openalex
- W6678127237 via openalex
- W1898670062 via openalex
- W1974620983 via openalex
- W1982376401 via openalex
- W1984421564 via openalex
- W1985520749 via openalex
- W1987759607 via openalex
- W1991915752 via openalex
- W1994404770 via openalex
Cited by (3)
- Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis 2012
- Bone Density in Adolescents Treated with a GnRH Agonist and Add-Back Therapy for Endometriosis 2007
- Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy (“draw-back” therapy) 2000
SciLite annotations
chemicals 6
fukanefuromarin c
withalongolide n
hydroxyproline
pyridinoline
deoxypyridinoline
estradiol
Source provenance
- europepmc
- last seen: 2026-06-19T06:14:56.452680+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:10:46.468712+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0
· commercial use OK